In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.

ADIA Nutrition Inc. (OTC Pink: ADIA), a leader in health and wellness solutions, has uncovered issues with share issuance ...

Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL ...

Researchers from the University of Illinois have identified a key process coordinating liver maturation and polyploidization, ...

A novel drug regimen tested for the first time by researchers at Fred Hutch Cancer Center has shown great promise in ...

A research team has identified a critical event driving tumor growth in a type of medulloblastoma -- and a way to block it.

All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...

Adia Nutrition's diverse portfolio, including its groundbreaking work in stem cell therapy through Adia Med, has positioned ...

A "courageous and brave" rugby player has died aged 27 after being diagnosed with leukaemia a year ago. Ellis Joseph's former ...

All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a ...

More than one-quarter of blood or marrow transplant survivors developed cutaneous malignant neoplasms, according to study results.Researchers identified several risk factors, including older age, ...